---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-027751"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2022-11-18T23:59:59+00:00"
generated_at: "2026-06-21T15:36:37.607427+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Diffusion Pharmaceuticals in active bidding stage, rejects LifeSci unsolicited bid; proxy contest looms

## Summary
- Board rejected unsolicited offer from LifeSci Capital client as 'woefully inadequate' and encouraged participation in strategic review.
- LifeSci-affiliated fund commenced proxy contest to replace Board nominees; Company says it lacks relevant industry expertise.
- Strategic review process at active bidding stage with multiple parties; Canaccord Genuity and Dechert LLP advising.
- 2022 Annual Meeting set for December 30, 2022, two weeks later than previously announced to focus on strategic review.

## SEC filing metadata
- accession: 0001437749-22-027751
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2022-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774922027751/0001437749-22-027751-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774922027751/dffn20221117_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-027751
- JSON: https://secwatch.observer/filing/0001437749-22-027751.json
- Plain text: https://secwatch.observer/filing/0001437749-22-027751.txt

## Key facts
- Earnings Releases
  CervoMed Inc. reported financial results for the three-month period ended September 30, 2022.
  - Period: the three-month period ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, Diffusion Pharmaceuticals Inc. (the “Company”) issued a press release announcing financial results for the three-month period ended September 30, 2022 and a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774922027751/0001437749-22-027751-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.